Introduction
A distinct line has traditionally been drawn between the pathophysiologies of idiopathic inflammatory myopathies (IIMs) and the genetic muscular dystrophies. Polymyositis, the most common of the IIMs, is a T-cell-mediated pathology in which a cellular immune response is a key feature in promoting muscle pathology [1] . Dermatomyositis pathology appears to derive primarily from a humoral immune response [1] . In contrast, the muscular dystrophies primarily result from mutation of a functionally diverse group of muscle proteins, including cytoskeletal proteins, basement membrane proteins, transmembrane proteins that are possibly involved in signaling, and nuclear envelope proteins or proteases [2] . However, the distinction between immune-mediated and nonimmunemediated muscle diseases has become less sharp, however, as more is learned of the complex, underlying pathogenic mechanisms in both IIMs and the muscular dystrophies. For example, a growing body of evidence shows that the immune system is a contributor to the pathology of some muscular dystrophies. In addition, exciting new findings indicate that key events initiating the pathology of IIMs may be independent of immune cell interactions with muscle. Although the IIMs and muscular dystrophies remain functionally meaningful and clinically valuable distinctions, learning more about the contributions of noninflammatory factors to the pathogenesis of IIMs and the contributions of inflammatory factors to the muscular dystrophies will help us understand better the relationships between skeletal muscle and the immune system in health and disease.
Immune cell involvement in dystrophinopathies
Mutation of the membrane-associated protein, dystrophin, causes the progressive muscle wasting and weakness that occurs in Duchenne muscular dystrophy (DMD), the milder Becker muscular dystrophy, and the mdx mouse model of DMD [2] . Dystrophin deficiency causes a weakening of the sarcolemma that can be mechanically damaged during muscle use [3] . This muscle membrane damage is expected to produce dysregulation of a broad spectrum of structural and regulatory genes in muscle [4] that eventually leads to muscle fiber death that is accompanied by muscle inflammation. Although inflammation has long been recognized as a feature of dystrophinopathy, it was generally dismissed as an epiphenomenon that reflected a nonspecific inflammatory response to muscle damage. However, the inflammatory infiltrate plays a major role in promoting the pathology of dystrophin-deficient muscle, at least in mdx mice. Depletions of macrophages from mdx mice prevent most muscle membrane lysis that is present at the peak of pathology [5] , suggesting that most muscle membrane lysis is attributable to macrophage cytotoxicity rather than mechanical lesions of the membrane.
Other observations have shown that a specific, cellular immune response can also promote dystrophinopathy. Most patients with DMD assayed expressed a highly conserved peptide in the hypervariable domain of the T-cell receptor in cytotoxic T lymphocytes (CTLs), which indicated that a specific immune response to a common antigen occurs in many patients with DMD [6] . Although the contribution of CTLs to the DMD pathology remains unexamined, recent findings show that expression of the CTLderived cytolytic protein, perforin, is elevated in DMD muscle [7 • ]. In previous studies using the mdx mouse model, depletion of CTLs produced a reduction in muscle pathology, and null mutation of perforin eliminated apoptosis and reduced necrosis in dystrophic muscle, suggesting that CTLs may also play a role in DMD [8] . However, more recent investigations indicate that perforinmediated apoptosis may not be an important feature of dystrophinopathy because overexpression of the antiapoptosis protein B-cell leukemia/lymphoma 2 (BCL-2) in mdx muscle produced no reduction in the histopathology of mdx muscles [9 •• ].
If T-cell-mediated pathology is a feature of dystrophinopathies or other muscle diseases, antigen presentation would be required for T-cell activation. Although expression of major histocompatibility complex (MHC) class I or II on dystrophic or IIM muscle has been long established [10, 11] , the expression of costimulatory molecules necessary for the stimulation and clonal expansion of auto-reactive T cells has been demonstrated only recently. Inducible costimulator ligand (ICOSL), a member of the B7 family of costimulatory molecules, can promote CTL activation by binding its receptor inducible costimulator (ICOS) present at the CTL surface [12 • ]. ICOSL expression was originally demonstrated on the surface of polymyositis, dermatomyositis, and inclusion body myositis (IBM) fibers [13] , which was consistent with a role for muscle fiber activation of auto-reactive T cells in IIMs. Surprisingly, more recent findings also show that ICOS and ICOSL are expressed in DMD muscle tissue at levels that are usually higher than the median expression level in IBM muscle [7 • ]. However, unlike polymyositis and dermatomyositis muscle, ICOSL is expressed primarily by mononucleated cells in the connective tissue in DMD muscle and expressed only weakly at the muscle fiber surface [7 • ]. Furthermore, ICOS-expressing CTLs are commonly observed invading the cytosol of IIM muscle fibers that express ICOSL and MHC class I, while ICOSLexpressing CTLs remain in the connective tissue surrounding muscle fibers in DMD [7 • ]. These findings indicate distinctions in CTL activation in DMD compared with the IIMs that are not yet understood.
Immune cell involvement in dysferlinopathies
Mutations in the dysferlin gene cause the progressive muscular dystrophies Miyoshi myopathy and limb girdle muscular dystrophy 2B [14 • ]. Observations that link dysferlin with membrane repair following cell damage suggest that mechanical damage to muscle fibers followed by defects in the repair process underlie the pathologic progression of the disease [14 • ]. Although defects in membrane repair following damage may be a primary pathogenic mechanism in dysferlinopathy, the prominent inflammatory infiltrate in dysferlin-deficient muscle suggests that inflammation may play a significant but unexplored role in promoting muscle damage. Furthermore, dysferlin-deficient fibers express MHC class I on their surfaces [15] [16] [17] , and complement activation precedes fiber necrosis, which implicates a nonspecific immune response in promoting fiber damage [18] . Macrophages, which are the most prevalent leukocyte population to invade dysferlin-deficient muscle, are found within or near injured fibers [18] , which would be consistent with their role in either causing or responding to muscle fiber damage. However, this inflammatory infiltrate is distinct from either IIMs or dystrophinopathies; limb girdle muscular dystrophy 2B or Myoshi myopathic muscle biopsies rarely contain CTLs, although CD4 + T-cell populations are greatly elevated [18] . Although dystrophin deficiency and dysferlin deficiency both involve muscle membrane damage that is associated with inflammation, there are scattered reports that are not yet well documented stating that treatment of patients with dysferlinopathy with anti-inflammatory corticosteroids may decrease muscle strength [16, 19] . If this is generally true for patients with dysferlinopathy, the observation would indicate important differences in inflammatory cell involvement compared with patients with DMD, in whom corticosteroids typically have beneficial effects.
Do nonimmune factors contribute to idiopathic inflammatory myopathy pathogenesis?
Our developing understanding of the role of the immune system in promoting the pathology of muscular dystrophies, in particular DMD and mdx dystrophy, suggests an interesting possibility: could nonimmune factors play a significant role in the pathogenesis of the IIMs? Although the pathologies of the major IIMs are certainly driven by autoimmunity, in each case the pathogenesis is unknown. Typically, autoantibodies expressed by patients with IIM recognize antigens that are expressed by tissues that do not experience an autoimmune pathology, illustrating the tissue specificity in the presentation of the antigens that is required for the autoimmune response [20 
The question of what conditions are necessary for developing a muscle-specific autoimmune disease became even more intriguing with the recent discoveries of Casciola-Rosen et al. [20 •• ] . In their analysis of the expression of the autoantigen Mi-2, against which 15-30% of patients with dermatomyositis express autoantibodies, they unexpectedly found that Mi-2 was expressed in muscle biopsies of healthy control participants. Similarly, other autoantigens that are present in dermatomyositis and polymyositis muscle, U1-70, HRS, and DNA-PK cs , were also present in healthy muscle. In each case, autoantigen expression was tremendously elevated after the clinical onset of the dermatomyositis or polymyositis. Further analysis showed that autoantigen expression was specifically elevated in muscle cells located in foci enriched in regenerating muscle fibers, proliferating myogenic cells, and inflammatory cells. These regions contained elevated concentrations of myogenic cells and myotubes that expressed markers of muscle development or regeneration, such as neural cell adhesion molecule and neonatal myosin heavy chain. These observations suggested the intriguing possibility that muscle regeneration was accompanied by elevation in autoantigen expression that eventually triggered an autoimmune response. In a scenario described by the investigators, muscle damage that induced muscle regeneration along with elevated MHC class I expression could provide the initial trigger for the ensuing autoimmune response. Interestingly, previous investigators have demonstrated that interferon-g can induce expression of MHC class II on proliferative myoblasts but not on fully differentiated muscle fibers [21] . This potential dependence on stage of muscle cell differentiation on the capacity for antigen presentation may be sufficient to explain the induction of autoimmunity by regenerative muscle, but not healthy muscle.
Immune-targeted interventions for the muscular dystrophies
Despite the accumulating evidence of immune cell involvement in promoting dystrophinopathies, uncertainties remain concerning whether the functional benefits of corticosteroid treatments in DMD or mdx dystrophies are primarily attributable to immunosuppression. Recent studies in young mdx mice confirm that treatment with prednisolone significantly decreased the concentrations of inflammatory cells in dystrophin-deficient skeletal muscle [22] . In addition, the prednisolone-treated mdx mice experienced reduced expression of cellular adhesion molecules by leukocytes and endothelial cells, suggesting that prednisolone's anti-inflammatory functions may be mediated by attenuating inflammatory cell extravasation into muscle. However, initiation of prednisolone therapy in mdx mice after the peak inflammatory phase of the disease did not have an effect on macrophage number, although gene array analysis showed induction of an anti-inflammatory expression profile [23] . For example, annexin A1, an expected mediator of glucocorticoid anti-inflammatory functions, was expressed at higher levels in prednisolonetreated animals, and expression of tumor necrosis factor (TNF) receptor was decreased [23] . Together, these findings show that prednisolone treatments in mdx dystrophy can have immunosuppressive effects if treatments are started early in the disease. This may be relevant to anecdotal reports that prednisolone treatments of DMD patients are more effective if they are begun at an early age. However, the findings do not eliminate the possibility that significant functional benefits may also derive from nonimmunosuppressive functions of prednisolone. Unfortunately, the clinical efficacy of prednisone is accompanied by negative side effects. Although a recent clinical study showed that DMD patients and their families perceived the benefits of intermittent prednisolone therapy to outweigh the adverse side effects [24] , development of specifically targeted immune interventions may offer greater promise for reducing the negative side effects associated with prednisolone treatments.
Functional blockade of TNF-a has been explored recently as a more specific therapeutic strategy for the treatment of dystrophinopathy, because TNF-a can promote inflammation, and its expression is increased in patients with DMD. However, whether perturbations of TNF-a expression or activity have a net beneficial effect on dystrophinopathy has not been demonstrated conclusively. Mdx mice treated with a soluble receptor fusion protein that binds TNF-a showed decreased mRNA for type I collagen and for the profibrotic cytokine transforming growth factor (TGF)-b1 in diaphragm muscles, which suggested that blocking TNF-a may attenuate fibrosis and thereby improve ventilatory function [25 • ]. However, treatment of mdx mice with an anti-human TNF-a antibody produced a less clearly beneficial outcome. Mdx mice receiving anti-human TNF-a showed delayed onset of pathology [26] , but the treatment also induced a cyclic pattern of pathology that perhaps reflected the weekly dosage regimen.
Continuing studies of the mechanisms through which anti-inflammatory drugs can affect the severity of muscular dystrophies have shown that some of the observed treatment effects may occur through direct action on muscle cells. For example, treatment of young mdx mice with the immunosuppressant cyclosporin prevented exerciseinduced loss of strength and fiber damage and decreased fibrosis, perhaps by attenuating TGF-b1 expression rather than by actions as an immunosuppressant [27 • ]. Interestingly, the cyclosporin treatment also inhibited the typical, dystrophic fast-to-slow fiber type transition, likely via calcineurin inhibition. A similar protective effect on fiber type transition, also attributed to calcineurin inhibition, was observed following prednisolone treatment [23] , although it is unknown whether functional benefits occurred.
Conversely, other experimental therapeutics intended to have beneficial effects by direct action on dystrophic muscle cells may be mediated in part through anti-inflammatory effects. For example, a recently completed pilot study of the effects of albuterol, a b 2 -agonist, on knee-extensor strength of patients with DMD showed beneficial effects on muscle strength that could reflect inhibition of calpainmediated proteolysis of muscle proteins that can be signaled through binding b 2 receptors [28 • ]. However, albuterol can also inhibit T-cell and macrophage activation [29-31], suggesting that the protective effect of albuterol in DMD may be attributable in part to its immunosuppressive functions.
Chemokines and their receptors as potential targets for therapeutics in muscular dystrophies and idiopathic inflammatory myopathies
The prominent involvement of the immune system in promoting the pathologies of IIMs and dystrophin deficiencies indicates that more specifically targeted immune interventions could be designed to disrupt disease-specific components of pathologic immune responses. The growing body of information concerning the roles of specific chemokines in the recruitment and activation of leukocytes suggests that disruption of chemokine-mediated signaling could be valuable in treatment of IIMs and muscular dystrophies in which inflammation is a pathologic feature. The use of chemokine receptor antagonists has already yielded promising results in rheumatoid arthritis, multiple sclerosis, and HIV [32 • ]. Recent findings have suggested several potential targets for disruption of chemokinemediated pathology in IIMs or muscular dystrophies. Beta-chemokine receptors (CCR) expressed on vascular endothelial cells and monocytes provide potential targets for affecting inflammatory cell invasion into diseased muscle, and the presence of CCR1, 4, and 5 expressed by muscle fibers themselves suggests their involvement in promoting an inflammatory response [33,34 • ,35 • ].
Although chemokines and their receptors may present potentially valuable therapeutic targets in muscle disease that have an inflammatory component, the large number of chemokines that are up-regulated in IIMs and dystrophin deficiency (Table 1) , and their redundancy of function may make the design of effective therapeutic interventions difficult. In addition, there are conflicting reports regarding CCR1 expression in the IIMs [34 • ,35 • ] that may be a result of inter-patient variability; this would indicate that a single therapeutic approach based on chemokine blockade may not be effective for all patients diagnosed with a common IIM. Furthermore, the identity of chemokines involved in promoting inflammation may differ between muscles and between stages of the pathology. For example, gene array and reverse transcription polymerase chain reaction analyses showed significant differences in the identity of chemokine ligands that were expressed at higher levels in the diaphragm or hind-limb muscles of mdx mice [33, 36] .
Although blocking chemokine-mediated signaling may provide a useful strategy for the treatment of IIMs and dystrophies in which there is inflammatory involvement, recent findings also show that chemokine-mediated signaling may also promote muscle regeneration. For example, ablation of CCR2 signaling in CCR2-null mice results in impaired muscle regeneration following injury [37 •• ]. Similarly, patients with dermatomyositis who experienced clinical improvement following intravenous immunoglobulin G therapy showed increased expression of a-chemokine ligands CXCL9 and CXCL11, suggesting they may have a beneficial role [38] . Therapeutic interventions based on disruptions of chemokine-mediated signaling will require careful dissection of the specific roles played by chemokines and their receptors in promoting immune cell-mediated damage or repair of muscle.
Conclusion
Recent advancements of our understanding of the pathogenesis of muscular dystrophies and IIMs reveal that the events that initiate and promote the pathologies of these muscle diseases are complex and subtle and display shared features between inflammatory myopathies and noninflammatory myopathies. Growing evidence shows a significant inflammatory cell involvement in promoting dystrophinopathies, and the extensive inflammatory cell involvement in dysferlinopathies suggests that similar immune cell involvement in the pathogenesis of these muscular dystrophies may also exist. Exciting new findings also indicate that early events that trigger the pathology of the best characterized IIMs may be nonimmunologic in at least some instances and result from a pathologic immune response to muscle regeneration following injury.
More specific and effective therapies for dystrophindeficient muscular dystrophies and for IIMs are needed.
Although corticosteroids and immunosuppressants such as cyclosporin can have beneficial effects, their lack of specificity limits their usefulness. Identification of specific inflammatory mediators that promote autoimmune or cytotoxic interactions between inflammatory cells and target muscle cells may allow the design of interventions that attenuate pathogenic mechanisms without disrupting regenerative processes.
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